Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Fascinating Fishing Objections From Around The World - 2Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 3Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- 46 US States for Fly Fishing
- 5Virtual reality opens doors for older people to build closer connections in real life
- Top 15 Web-based Entertainment Stages for Individual Marking
- Manual for Tracking down One of a kind Store Inns
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- Most loved Seared Chicken: Which Chain Rules?
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Figure out How to Track the Establishment of New 5G Pinnacles
- Four Dead in Last Month From Animal Attacks in Nepal
- Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- The Most Rousing Ladies Business visionaries of Today
